ClinicalTrials.gg
RecruitingNCT04311073Updated Sep 11, 2023

Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies

A Phase 3 interventional study of Tranexamic Acid and Placebos in Fibroid Uterus, Abnormal Uterine Bleeding and Myoma;Uterus, sponsored by Eastern Virginia Medical School. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Eastern Virginia Medical School · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 156 studies in Leiomyoma with a site in United States — 19 open to participants now, 29 under way, 3 of them phase 3. Leiomyoma · United States.

Planned enrollment
66th of 121
50 · median 57
Started
2020
with 7 others
Phase 3
31 of 156
2 open now
Primary completion
2024-07
later than 0 of 27 live
Registered
111th of 156
by date

Among the 156 studies in Leiomyoma with a site in United States, this one is the 66th largest by planned enrollment of the 121 interventional ones that give a count, is one of 8 that started in 2020, is one of 31 in phase 3, reaches primary completion later than 0 of the 27 other live ones, and was the 111th registered.

Leiomyoma

439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

19 of the 156 studies in Leiomyoma with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies in Leiomyoma with a site in United States, or all of them as a file.
02

Study summary

This is a Double-blinded randomized placebo-controlled trial based at Eastern Virginia Medical School. Subjects who are identified in clinic having menorrhagia or abnormal Uterine bleeding (AUB) due to uterine fibroids and meet inclusion criteria based on the ultrasound (US) or Magnetic Resonance Imaging (MRI), aged 18-45 undergoing laparoscopic or Robotic assisted myomectomies. A total of 50 women in each arm of the study with symptomatic fibroids. Patients will be randomized to receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline (intervention group) versus an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision.

Read the detailed description

This is a Double-blinded randomized placebo-controlled trial based at Eastern Virginia Medical School. Subjects who are identified in clinic having menorrhagia or abnormal Uterine bleeding (AUB) due to uterine fibroids and meet inclusion criteria based on the ultrasound (US) or Magnetic Resonance Imaging (MRI), aged 18-45 undergoing laparoscopic or Robotic assisted myomectomies. These subjects will be then approached for consent during their pre-op visit 1-2 weeks prior to their surgery. The setting for consent will be in a patient consultation room. A total of 50 women in each arm of the study with symptomatic fibroids meeting any of the following criteria will be included in the study:

  1. At least one fibroid greater than or equal to 6 cm
  2. Any intramural or broad ligament fibroid greater than or equal to 4 cm
  3. At least 3 total fibroids based on preoperative imaging. Randomization will be performed using an automated randomization website Patients will be randomized to receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline (intervention group) versus an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision. This dosage will not be adjusted for patients with renal insufficiency as they will be excluded from the study. Preparation of the medications will be performed by anesthesia who have both medication and normal saline available to them on short notice. No prior preparation by pharmacy will be required. Tranexamic acid is readily available in a 10 ml vial, which does not need a pharmacist to prepare for administration. The vial is mixed with 50 ml of saline in the operating room. This is the same process that occurs outside of any study with any medication that is administered intra-operatively. This will in no way impact the patient's safety during the surgery, especially since it is administered 15 minutes prior to the start of the procedure.

Both surgeon and patient will be blinded to the treatment arm. This dosage has been used previously in both obstetric and gynecological procedures and is the same dose recommended by the WHO for preventing post-partum hemorrhage The surgery itself will be scheduled at either Sentara Norfolk General, Sentara Leigh hospital, and Sentara Princess Anne hospital. These are the three sites that the investigators already perform Minimally invasive myomectomies.

An envelope will be given to the anesthesiologist prior to the procedure informing whether they are to receives TXA or the placebo. Blood loss will be estimated by the surgeon performing the procedure. Hemoglobin and hematocrit will be obtained 24 hours post procedure. The patient will be assessed for reported side effects from the medication given will be assessed by a questionnaire that will be given at their post-op appointment at the 2 week and 6-week mark. During these two visits a physical exam is performed, checking incision sites, and patient symptoms, all of which are standard of care for any minimally invasive procedure. The patients will be seen at the EVMS outpatient clinic for Gynecology, or depending with the physician who performed the surgery. Data will be collected from both Allscripts and EPIC charts.

03

Conditions studied

  • Fibroid Uterus
  • Abnormal Uterine Bleeding
  • Myoma;Uterus

Keywords

  • Tranexamic acid
  • Minimally Invasive
  • Myomectomy
  • Fibroid
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing laparoscopic myomectomy
  • At least one fibroid greater than or equal to 6 cm
  • Any intramural or broad ligament fibroid greater than or equal to 4 cm
  • At least 3 total fibroids based on preoperative imaging

Exclusion criteria

Exclusion Criteria:

  • Severe existing medical complications involving the heart, liver, or kidney
  • Moderate to severe renal impairment (serum creatinine > 1.4)
  • Blood clotting abnormalities
  • Known Allergies to tranexamic acid
  • Known to Minimally invasive myomectomies
  • If you are pregnant
  • History of a prior blood clot in the lung arm or leg, known as pulmonary embolism or deep vein thrombosis
  • Any active blood clots, clotting disease, pulmonary embolism, cerebral thrombosis, estrogen use, renal impairment, elevated creatinine level
  • History of a stroke or mini-strokes
  • Concurrent oral use
  • Contraindications to receiving Tranexamic acid
  • In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity
  • In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients.
  • In patients with active intravascular clotting.
  • In patients with to tranexamic acid or any of the ingredients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Tranexamic Acid

    Patients will receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline 15 minutes prior to initial surgical incision time

    Drug: Tranexamic Acid

  • Placebo comparator
    Placebo

    Patients will receive an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision

    Drug: Placebos

Interventions

  • IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.

  • DrugPlacebos

    IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.

06

What researchers measure

Primary outcomes

  1. Estimated blood loss

    Estimated blood loss at time of procedure completion; using volume of cannister and weight of lap sponges

    Time frame: Duration of procedure up to 420 minutes

  2. Calculated blood loss

    Calculated Blood loss, using pre-operative hematocrit, postoperative hematocrit and estimated blood volume x Body Mass Index

    Time frame: From post operative day 0 until postoperative day 1

  3. Number of blood products received

    Number of blood products received during admission that is directly due to blood loss at time of procedure

    Time frame: Duration of hospital stay up to two days

Secondary outcomes

  1. Duration of surgery

    Start time of procedure until end time of procedure

    Time frame: Duration of surgery up to 420 minutes

  2. Length of hospital stay

    Recorded in days

    Time frame: Duration of stay in hospital, up to two days

  3. Number of fibroids removed

    Total number of fibroids removed during procedure

    Time frame: Duration of surgery, up to 420 minutes

  4. Fibroid type

    type of fibroid per FIGO classification

    Time frame: through completion of study average 8 weeks

  5. Weight of fibroids removed

    total weight of fibroids removed

    Time frame: duration of surgery up to 420 minutes

  6. Pain index

    Pain index score on postoperative day 1 and 14 Score of 0-10 0 = no pain, 10 = significant amount of pain

    Time frame: duration of hospital stay, up to two days

  7. Incidence of postoperative complication

    Immediate postoperative complication: Hemorrhage Infection Fever Deep vein thrombosis Hysterectomy Re-exploration Hospital readmission

    Time frame: Duration of hospital stay , up to two days

  8. Questionnaire for incidence of mild side effect of medication

    Reported mild effective of medication of post operative day 1

    Time frame: only on postoperative day 1 , one day

  9. Questionnaire for incidence of serious side effect of medication

    Reported serious side effect of medication on post operative day 1

    Time frame: Only on postoperative day 1, one day

  10. tPA receptor

    Percentage of tPA receptor located in fibroid and myometrium

    Time frame: From time of randomization until postoperative visit, four weeks

  11. PAI-1 receptor

    Percentage of PAI-1receptor located in fibroid and myometrium

    Time frame: From time of randomization until postoeprative visit, four weeks

07

Study locations

1 of 1 sites recruiting
  • EasternVMC
    Norfolk, Virginia 23507, United States
    Recruiting
08

References and documents

Publications

  • Topsoee MF, Settnes A, Ottesen B, Bergholt T. A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery. Int J Gynaecol Obstet. 2017 Feb;136(2):120-127. doi: 10.1002/ijgo.12047. Epub 2016 Dec 9. PubMed 28099726 ↗
  • Moore EE, Moore HB, Gonzalez E, Chapman MP, Hansen KC, Sauaia A, Silliman CC, Banerjee A. Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid. J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S65-9. doi: 10.1097/TA.0000000000000634. PubMed 26002266 ↗
  • Hickman LC, Kotlyar A, Shue S, Falcone T. Hemostatic Techniques for Myomectomy: An Evidence-Based Approach. J Minim Invasive Gynecol. 2016 May-Jun;23(4):497-504. doi: 10.1016/j.jmig.2016.01.026. Epub 2016 Mar 9. Erratum In: J Minim Invasive Gynecol. 2019 Feb;26(2):373. doi: 10.1016/j.jmig.2019.01.001. PubMed 26855249 ↗
  • Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD001886. doi: 10.1002/14651858.CD001886.pub3. PubMed 21249650 ↗
  • Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2014 Aug 15;2014(8):CD005355. doi: 10.1002/14651858.CD005355.pub5. PubMed 25125317 ↗
  • Opoku-Anane J, Vargas MV, Moawad G, Cherie M, Robinson JK. Use of Intravenous Tranexamic Acid During Myomectomy: A Randomized Double-Blind Placebo Controlled Trial. J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S197. doi: 10.1016/j.jmig.2015.08.715. Epub 2015 Oct 15. No abstract available. PubMed 27679021 ↗
  • Parker WH. Uterine myomas: management. Fertil Steril. 2007 Aug;88(2):255-71. doi: 10.1016/j.fertnstert.2007.06.044. Epub 2007 Jul 20. PubMed 17658523 ↗
  • Lam SJ, Best S, Kumar S. The impact of fibroid characteristics on pregnancy outcome. Am J Obstet Gynecol. 2014 Oct;211(4):395.e1-5. doi: 10.1016/j.ajog.2014.03.066. Epub 2014 Apr 3. PubMed 24705132 ↗
  • WHO Recommendation on Tranexamic Acid for the Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2017. Available from http://www.ncbi.nlm.nih.gov/books/NBK493081/ PubMed 29630190 ↗
  • Ngichabe S, Obura T, Stones W. Intravenous tranexamic acid as an adjunct haemostat to ornipressin during open myomectomy. A randomized double blind placebo controlled trial. Ann Surg Innov Res. 2015 Oct 31;9:10. doi: 10.1186/s13022-015-0017-y. eCollection 2015. PubMed 26568770 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jul 2024, 49 months after the start.

Of 25 phase 3 interventional studies under Leiomyoma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 41. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Mar 17, 2020
StartActual
Jun 20, 2020
Primary completionEst.
Jul 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04311073
Lead sponsor
Eastern Virginia Medical School
Responsible party
Sponsor
First posted
Mar 17, 2020
Start date
Jun 20, 2020
Primary completion
Jul 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 11, 2023

Study contacts

Seifeldin Sadek, MD
Contact
sadeks@evms.edu
7574467100
Traci Ito, MD
Contact
itoTE@evms.edu
7574467900
Seifeldin Sadek, MD
principal investigator · Eastern Virginia Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion